(Q34695710)

4 August 2017

1 reference

title

Guidelines on bladder cancer (English)

1 reference

4 August 2017

4

Per-Uno Malmström

1 reference

4 August 2017

Willem Oosterlinck

1

1 reference

4 August 2017

Bernard Lobel

2

1 reference

4 August 2017

Gerhard Jakse

3

1 reference

4 August 2017

Michael Stöckle

5

1 reference

4 August 2017

Cora Sternberg

6

1 reference

4 August 2017

European Association of Urology (EAU) Working Group on Oncological Urology

7

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

4 August 2017

1 reference

4 August 2017

41

1 reference

4 August 2017

105-112

1 reference

4 August 2017

2

1 reference

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

The prostate involvement as prognostic factor in patients with superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

The treated natural history of high risk superficial bladder cancer: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Factors affecting recurrence and progression in superficial bladder tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Complications of ileal conduit diversion in adults with cancer followed up for at least five years

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Continent diversion with the Mainz pouch

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

When the bladder is gone: quality of life following different types of urinary diversion

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Sexual function following radical radiotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Prognostic factors in patients with bladder carcinoma treated with definitive irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Chemotherapy and management of bladder tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Neo-adjuvant chemotherapy in invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Local recurrence after cystectomy alone for bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

Upper tract tumours following cystectomy for bladder cancer. Is routine intravenous urography worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900026-4

7 January 2021

10.1016/S0302-2838(01)00026-4

Identifiers

DOI

1 reference

4 August 2017

1 reference